Iovance Reports Final Phase 2 Melanoma Therapy Results at ESMO

Final analysis of lifileucel plus pembrolizumab in frontline advanced melanoma showed a 62.5% confirmed objective response rate and a 29.2% complete response rate. Median overall survival was not reached after more than four years of median follow-up.